S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.38%) $966.30
USD/EUR
(-0.36%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.36%) $91.45

Actualizaciones en tiempo real para Aarti Drugs Limited [AARTIDRUGS.NS]

Bolsa: NSE Sector: Healthcare Industria: Drug Manufacturers—Specialty & Generic
Upcoming Earnings Alert

Quarter results today
(bmo 2024-05-03)

Expected move: +/- 4.13%

Última actualización3 may 2024 @ 05:59

0.36% INR 502.60

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 05:59):

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene...

Stats
Volumen de hoy 97 764.00
Volumen promedio 210 437
Capitalización de mercado 46.21B
EPS INR0 ( 2024-04-13 )
Próxima fecha de ganancias ( INR0 ) 2024-07-18
Last Dividend INR1.000 ( 2023-02-08 )
Next Dividend INR0 ( N/A )
P/E 25.67
ATR14 INR1.356 (0.27%)

Volumen Correlación

Largo: -0.14 (neutral)
Corto: -0.62 (weak negative)
Signal:(42.814) Neutral

Aarti Drugs Limited Correlación

10 Correlaciones Más Positivas
BBL.NS0.955
RBLBANK.NS0.954
AIRAN.NS0.949
PGHH.NS0.944
KELLTONTEC.NS0.94
HPL.NS0.94
PREMEXPLN.NS0.939
SJVN.NS0.938
TWL.NS0.936
POLYCAB.NS0.934
10 Correlaciones Más Negativas
LTGILTBEES.NS-0.947
SINTEX.NS-0.924
RAJRILTD.NS-0.922
BOHRAIND.NS-0.92
RAJVIR.NS-0.911
BGLOBAL.NS-0.906
IRISDOREME.NS-0.906
OMAXE.NS-0.905
JPINFRATEC.NS-0.903
SRPL.NS-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aarti Drugs Limited Correlación - Moneda/Commodity

The country flag -0.55
( weak negative )
The country flag -0.52
( weak negative )
The country flag -0.24
( neutral )
The country flag -0.67
( moderate negative )
The country flag -0.71
( moderate negative )
The country flag -0.61
( weak negative )

Aarti Drugs Limited Finanzas

Annual 2022
Ingresos: INR27.16B
Beneficio Bruto: INR8.28B (30.47 %)
EPS: INR17.96
FY 2022
Ingresos: INR27.16B
Beneficio Bruto: INR8.28B (30.47 %)
EPS: INR17.96
FY 2022
Ingresos: INR24.89B
Beneficio Bruto: INR5.04B (20.24 %)
EPS: INR22.12
FY 2021
Ingresos: INR21.55B
Beneficio Bruto: INR6.00B (27.86 %)
EPS: INR30.09

Financial Reports:

No articles found.

Aarti Drugs Limited Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
INR0
(N/A)
INR0
(N/A)
INR1.000
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)

Aarti Drugs Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.77 - low (58.39%) | Divividend Growth Potential Score: 3.35 - Decrease likely (33.07%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend INR0.150 2003-11-13
Last Dividend INR1.000 2023-02-08
Next Dividend INR0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 32 --
Total Paid Out INR15.88 --
Avg. Dividend % Per Year 0.23% --
Score 2.13 --
Div. Sustainability Score 4.77
Div.Growth Potential Score 3.35
Div. Directional Score 4.06 --
Next Divdend (Est)
(2024-10-31)
INR0 Estimate 0.00 %
Dividend Stability
0.08 Very Bad
Dividend Score
2.13
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2003 INR0 0.00%
2004 INR0 0.00%
2005 INR0 0.00%
2006 INR0 0.00%
2007 INR0 0.00%
2008 INR0 0.00%
2009 INR0 0.00%
2010 INR0 0.00%
2011 INR0 0.00%
2012 INR0 0.00%
2013 INR0 0.00%
2014 INR0 0.00%
2015 INR0 0.00%
2016 INR0 0.00%
2017 INR0 0.00%
2018 INR0.250 0.18%
2019 INR0.250 0.17%
2020 INR3.00 2.03%
2021 INR0 0.00%
2022 INR1.000 0.18%
2023 INR1.000 0.22%
2024 INR0 0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
RVNL.NS Dividend Knight 2023-09-20 Annually 6 3.08%
LSIL.NS Dividend Junior 2023-07-17 Annually 3 0.23%
GEOJITFSL.NS Dividend Knight 2023-06-30 Annually 20 2.79%
ARVIND.NS Dividend Junior 2023-07-21 Sporadic 20 0.59%
THEMISMED.NS Dividend Junior 2023-08-31 Sporadic 18 0.39%
ORIENTELEC.NS Dividend Junior 2023-07-26 Semi-Annually 7 0.41%
IRFC.NS Dividend Junior 2023-09-15 Annually 4 2.61%
CUB.NS Dividend Junior 2023-08-11 Annually 23 0.35%
SHRADHA.NS Dividend Junior 2023-07-06 Sporadic 6 0.99%
MAPMYINDIA.NS Dividend Junior 2023-08-25 Annually 3 0.13%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06801.5008.6410.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.1501.5009.4410.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM8.411.0008.008.00[3 - 30]
operatingCashFlowPerShareTTM10.962.006.3510.00[0 - 30]
freeCashFlowPerShareTTM10.962.004.529.04[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.3221.0007.967.96[0.2 - 0.8]
operatingProfitMarginTTM0.1051.0009.919.91[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score4.77

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM25.471.0007.530[1 - 100]
returnOnEquityTTM0.1502.509.6410.00[0.1 - 1.5]
freeCashFlowPerShareTTM10.962.006.359.04[0 - 30]
dividendYielPercentageTTM0.2001.5004.990[0 - 0.4]
operatingCashFlowPerShareTTM10.962.006.3510.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.3491.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.03801.000-1.5500[0.1 - 0.5]
Total Score3.35

Aarti Drugs Limited

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico